Latest filings (excl ownership)
8-K
Entry into a Material Definitive Agreement
18 Apr 24
NT 10-K
Notice of late annual filing
18 Mar 24
8-K
Nebula Genomics secures major international B2B deal – Additional significant B2B deals in final stages
15 Mar 24
8-K
ProPhase poised to ramp up growth at Pharmaloz and Nebula Genomics in 2024
4 Jan 24
10-Q
2023 Q3
Quarterly report
13 Nov 23
8-K
ProPhase Labs Announces Financial Results
9 Nov 23
10-Q
2023 Q2
Quarterly report
11 Aug 23
8-K
ProPhase Labs Announces Financial Results
10 Aug 23
8-K
Navidea Biopharmaceuticals Rejects ProPhase Labs Offer To Acquire Certain Assets of Navidea
29 Jun 23
8-K
Regulation FD Disclosure
22 Jun 23
8-K
Amendments to Articles of Incorporation or Bylaws
20 Jun 23
8-K
Departure of Directors or Certain Officers
20 Jun 23
10-Q
2023 Q1
Quarterly report
12 May 23
8-K
ProPhase Labs Announces Financial Results
11 May 23
ARS
2022 FY
Annual report to shareholders
27 Apr 23
DEF 14A
Definitive proxy
27 Apr 23
8-K
Regulation FD Disclosure
25 Apr 23
8-K
Departure of Directors or Certain Officers
6 Apr 23
10-K
2022 FY
Annual report
29 Mar 23
8-K
ProPhase Labs Announces Record Financial Results
28 Mar 23
8-K
ProPhase Labs Announces New $6 Million Stock Repurchase Program
15 Mar 23
8-K
Company in Early Stages of Exploring Development for Commercialization in Other Countries
1 Mar 23
8-K
Goal to launch commercially in Q4 2023
22 Feb 23
8-K
ProPhase Labs Announces Plans for Major Expansion of its Pharmaloz Manufacturing, Inc. Subsidiary to Meet Growing Demand
15 Feb 23
8-K
ProPhase Labs Provides Update on Linebacker-1 Cancer Co-Therapy Program and Outlines Development Strategy
6 Feb 23
8-K
Entry into a Material Definitive Agreement
30 Jan 23
8-K
ProPhase Labs Closes Acquisition of BE-Smart Esophageal Pre-Cancer Diagnostic Screening Test
5 Jan 23
8-K
Departure of Directors or Certain Officers
28 Dec 22
8-K
ProPhase Labs Acquires Rights to Novel Esophageal Cancer Test
20 Dec 22
S-8
Registration of securities for employees
14 Nov 22
10-Q
2022 Q3
Quarterly report
10 Nov 22
8-K
ProPhase Labs Announces Record Third Quarter 2022 Financial Results
10 Nov 22
8-K
ProPhase Labs Announces Collaboration with Dana-Farber Cancer Institute
8 Nov 22
8-K
ProPhase Labs Announces Collaboration with G42 Healthcare
19 Oct 22
8-K
Departure of Directors or Certain Officers
7 Oct 22
10-Q
2022 Q2
Quarterly report
12 Aug 22
8-K
ProPhase Labs Announces Record Second Quarter 2022 Financial Results
11 Aug 22
8-K
ProPhase Labs Announces New $6 Million Stock Repurchase Plan
26 Jul 22
8-K
ProPhase Labs Announces Licensing of New Investigational Cancer Compounds
21 Jul 22
8-K
Regulation FD Disclosure
19 Jul 22
Latest ownership filings
4/A
Ted William Karkus
21 Mar 24
4
Jed Latkin
19 Mar 24
3
Jed Latkin
19 Mar 24
4
Warren Hirsch
19 Mar 24
4
LOUIS MD GLECKEL
19 Mar 24
4
Jason Michael Barr
19 Mar 24
4
Ted William Karkus
19 Mar 24
SC 13D/A
Karkus Ted William
19 Mar 24
SC 13G/A
Lantern Pharma Inc.
14 Feb 24
4/A
Warren Hirsch
22 Jun 23
4/A
LOUIS MD GLECKEL
22 Jun 23
4/A
Jason Michael Barr
22 Jun 23
4
Warren Hirsch
21 Jun 23
4
Jason Michael Barr
21 Jun 23
4
LOUIS MD GLECKEL
21 Jun 23
4
Robert A. Jr. Morse
6 Apr 23
4
Ted William Karkus
5 Apr 23
SC 13D/A
Karkus Ted William
5 Apr 23
4
Ted William Karkus
4 Apr 23
SC 13D/A
Karkus Ted William
4 Apr 23
4
Ted William Karkus
2 Feb 23
SC 13D/A
Karkus Ted William
2 Feb 23
4
Ted William Karkus
17 Jan 23
SC 13D/A
Karkus Ted William
17 Jan 23
3
Robert A. Jr. Morse
13 Jan 23
SC 13G
Lantern Pharma Inc.
21 Nov 22
SC 13D/A
Karkus Ted William
18 Oct 22
4
Ted William Karkus
18 Oct 22
SC 13D/A
Karkus Ted William
11 Aug 22
4
Ted William Karkus
10 Aug 22
4
Jason Michael Barr
5 Jul 22
4
LOUIS MD GLECKEL
5 Jul 22
4
Warren Hirsch
5 Jul 22
SC 13D/A
Karkus Ted William
26 May 22
4
Ted William Karkus
25 May 22
4
Monica L. Brady
25 May 22
3
Billy Joe White
23 May 22
4/A
Jason Michael Barr
11 Apr 22
4
Jason Michael Barr
16 Mar 22
4
Warren Hirsch
10 Jun 21